This means that even if a patient is evaluated as having low expression of both GPX4 and FSP1, there may be cancer cells with relatively high expression of both GPX4 and FSP1, and these cells may affect the outcome of cancer treatment strategies with ferroptosis. This evidence concerns the gene GPX4 and cancer.